National Research Corporation (NRC)
NASDAQ: NRC · IEX Real-Time Price · USD
34.97
0.00 (0.00%)
At close: May 3, 2024, 4:00 PM
34.87
-0.10 (-0.29%)
After-hours: May 3, 2024, 4:03 PM EDT

National Research Revenue

In the year 2023, National Research had annual revenue of $148.58M, a decrease of -1.97%. Revenue in the quarter ending December 31, 2023 was $38.00M, a -0.37% decrease year-over-year.

Revenue (ttm)
$148.58M
Revenue Growth
-1.97%
P/S Ratio
5.60
Revenue / Employee
$341,563
Employees
435
Market Cap
831.80M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023148.58M-2.99M-1.97%
Dec 31, 2022151.57M3.61M2.44%
Dec 31, 2021147.95M14.68M11.01%
Dec 31, 2020133.28M5.30M4.14%
Dec 31, 2019127.98M8.30M6.93%
Dec 31, 2018119.69M2.13M1.81%
Dec 31, 2017117.56M8.18M7.47%
Dec 31, 2016109.38M7.04M6.88%
Dec 31, 2015102.34M3.51M3.55%
Dec 31, 201498.84M6.25M6.75%
Dec 31, 201392.59M6.17M7.14%
Dec 31, 201286.42M10.65M14.06%
Dec 31, 201175.77M12.37M19.51%
Dec 31, 201063.40M5.71M9.89%
Dec 31, 200957.69M6.68M13.09%
Dec 31, 200851.01M2.09M4.27%
Dec 31, 200748.92M5.15M11.77%
Dec 31, 200643.77M11.33M34.95%
Dec 31, 200532.44M2.75M9.28%
Dec 31, 200429.68M2.76M10.25%
Dec 31, 200326.92M4.54M20.26%
Dec 31, 200222.39M4.71M26.67%
Dec 31, 200117.67M-642.13K-3.51%
Dec 31, 200018.32M132.11K0.73%
Dec 31, 199918.18M519.33K2.94%
Dec 31, 199817.66M1.38M8.48%
Dec 31, 199716.28M3.68M29.24%
Dec 31, 199612.60M3.68M41.30%
Dec 31, 19958.92M2.16M32.01%
Dec 31, 19946.75M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
HealthStream 282.88M
Definitive Healthcare 251.42M
Paragon 28 216.39M
Evolus 202.09M
Sage Therapeutics 91.06M
REGENXBIO 90.24M
Mesoblast 7.25M
Pliant Therapeutics 1.58M
Revenue Rankings